Rousselot Biomedical to Present New Study on X-Pure at CPhI Worldwide 2019
Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.
Rousselot Biomedical, a collagen-based solutions manufacturer headquartered in The Netherlands, announced it will present the results of a recent study of its endotoxin-purified gelatin, X-Pure, at CPhI Worldwide on Nov. 5–7, 2019 in Frankfurt, Germany.
According to an Oct. 17, 2019 press release, the Rousselot Expertise Center and UMC Utrecht, a university hospital located in The Netherlands, conducted a study on the role of endotoxins in gelatin on mesenchymal stem cells and peripheral blood mononuclear cells and their influence on cellular activity. The teams came to the conclusion that Rousselot’s X-Pure provided a superior environment for stem cell viability and differentiation.
Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.
Rousselot Biomedical will also be showcasing at booth 120D21 at the event.
Source: Rousselot Biomedical
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
